期刊文献+

细胞视黄酸结合蛋白Ⅱ、表皮型脂肪酸结合蛋白及Ki-67在乳腺浸润性导管癌中的表达及相关性 被引量:3

Expression of CRABPⅡ,E-FABP and Ki67 in Breast Invasive Ductal Carcinoma and heir Correlation
原文传递
导出
摘要 目的研究细胞视黄酸结合蛋白(CRABP)Ⅱ、表皮型脂肪酸结合蛋白(E-FABP)和Ki-67在乳腺浸润性导管癌中的表达情况及三者的相关性。方法采用免疫组织化学检测2001年1月-2007年12月手术切除的152例乳腺浸润性导管癌中CRABPⅡ、E-FABP和Ki-67的表达。结果在浸润性导管癌中,CRABPⅡ在Ki-67阴性组的阳性率高于Ki-67阳性组(P<0.05),相反地,E-FABP在Ki-67阳性组的阳性率高于Ki-67阴性组(P<0.05)。CRABPⅡ和Ki-67表达呈负相关(rS=0.432,P<0.05);E-FABP和Ki-67表达呈正相关(rS=0.842,P<0.05)。E-FABP和Ki-67的表达具有协同性,E-FABP和Ki-67共同表达与肿瘤的转移有关(P<0.05)。单因素生存分析显示,E-FABP的阳性表达患者、Ki-67的阳性表达患者以及E-FABP和Ki-67的共同阳性表达患者的预后差(P<0.05)。多因素生存分析提示E-FABP的表达(RR=4.223,P=0.012)和TNM分期(RR=8.412,P=0.000)是影响浸润性导管癌患者预后的独立危险因素。结论在乳腺浸润性导管癌中,CRABPⅡ和E-FABP与肿瘤细胞的增殖有关,CRABPⅡ抑制细胞增殖,E-FABP促进细胞增殖。E-FABP和Ki-67在浸润性导管癌的发生、发展中起协同作用,两者的阳性表达可能对评估肿瘤的转移和患者的预后有一定价值。 Objective To investigate the expression of CRABP Ⅱ , E-FABP and Ki67 in breast invasion ductal carcinoma (IDC) and their correlation. Methods CRABP Ⅱ , E-FABP and Ki67 were detected in 152 cases of IDC removed from January 2001 to December 2007 by immunohistochemical staining. Results The expression of CRABP Ⅱ had a recognizable advantage in Ki67-negative group than Ki67-positive group. E-FABP had a recognizable advantage in Ki67-positive group than Ki67-negative group (P 〈 0.05). There was a significant negative correlation between CRABP H and Ki67 (r=-0.432, P 〈 0.05), while positive correlation existed between E-F'ABP and Ki67 (r=0.842, P 〈 0.05). The expression of Ki67 coordinated with E-FABP, and their co-expression was correlated with tumor metastasis (P 〈 0.05). Single survival analysis indicated that the E-FABP positive expression, Ki67 positive expression and their co-expression were associated with postoperative survival rate of IDC patients (P 〈 0.05). The multivariate analysis using the COX regression model identified that E-FABP was independent prognostic factor of IDC patients (P 〈 0.0). Condusions CRABP Ⅱ and E-FABP are relevant to cell proliferation in IDC patients. CRABP Ⅱ inhibits cell proliferation, while E-FABP promotes cell proliferation. The expression of E-FABP and Ki67 has a synergistic action in IDC, which is related to tumor metastasis and prognosis.
出处 《华西医学》 CAS 2013年第9期1415-1419,共5页 West China Medical Journal
基金 四川省卫生厅科研课题(100174)~~
关键词 乳腺肿瘤 浸润性导管癌 细胞视黄酸结合蛋白Ⅱ 表皮型脂肪酸结合蛋白 KI-67抗原 Breast neoplasms Invasive ductal carcinoma CRABP Ⅱ E-FABP Ki67 antigen
  • 相关文献

参考文献16

  • 1Schug TT, Berry DC, Shaw NS, et al. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors[J]. Cell, 2007, 129(4): 723-733.
  • 2Rochette-Egly C, Chambon P. F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling[J]. Histol Histopathol, 2001, 16(3): 909-922.
  • 3Donato LJ, Suh JH, Noy N. Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling[J]. Cancer Res, 2007, 67(2): 609-615.
  • 4Donato L J, Noy N. Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein 1I signaling[J]. Cancer Res, 2005, 65(18): 8193-8199.
  • 5Di-Poi N, Tan NS, Michalik L, et al. Antiapoptotic role of PPAR beta in keratinocytes via transcriptional control of the aktl signalingpathway[J]. Mol Cell, 2002, 10(4): 721-733.
  • 6Vo HP, Crowe DL. Transcriptional regulation of retinoic acid responsive genes by cellular retinoic acid binding protein-llmodulates RA mediated tumor cell proliferation and invasion[J]. Anticancer Res, 1998, 18(1A): 217-224.
  • 7Budhu AS, Noy N. Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest[J]. Mol Cell Biol, 2002, 22(8): 2632-2641.
  • 8Manor D, Shmidt EN, Budhu A, et al. Mammary carcinoma suppression by cellular retinoic acid binding protein- 1I [J]. Cancer Res, 2003, 63(15): 4426-4433.
  • 9汤参娥,李萃,肖志强,章晓鹏,陈主初,易红,李建玲,段朝军,梁宋平.人肺鳞癌组织的比较蛋白质组学研究[J].中华肿瘤杂志,2006,28(4):274-279. 被引量:14
  • 10Fuj K, Kondo T, Yokoo H, et al. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye[J]. Proteomies, 2005, 5(5): 1411-1422.

二级参考文献56

  • 1Simpson PT,Reis-Filho JS,Lakhani SR.Breast pathology:beyond morphology.Semin Diagn Pathol,2010,27(1):91-96.
  • 2Ravdin PM,Siminoff LA,Davis GJ,et al.Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.J Clin Oncol,2001,19(4):980-991.
  • 3Coldhirsch A,Ingle JN,Gelber RD,et al.Thresholds for therapies:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.Ann Oncol,2009,20(8):1319-1329.
  • 4Carey LA.Through a glass darkly:advances in understanding breast cancer biology,2000-2010.Clin Breast Cancer,2010,10(3):188-195.
  • 5Jatoi I,Anderson WF,Rosenberg PS.Qualitative age-interactions in breast cancer:a tale of two diseases? Am J Clin Oncol,2008,31(5):504-506.
  • 6Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study.JAMA,2006,295(21):2492-2502.
  • 7Silverstein MJ.The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast.Am J Surg,2003,186(4):337-343.
  • 8Carter CL,Allen C,Henson DE.Relation of tumor size,lymph node status,and survival in 24,740 breast cancer cases.Cancer,1989,63(1):181-187.
  • 9American Joint Committee on Cancer.AJCC Cancer Staging Handbook.7th ed.Chicago:Springer,2010.
  • 10Goyal A,Mansel RE.Recent advances in sentinel lymph node biopsy for breast cancer.Curr Opin Oncol,2008,20(6):621-626.

共引文献26

同被引文献34

  • 1Donato L J, Noy N. Suppression of mammary carcinoma growth by retinoic acid proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein 1I signaling[J]. Cancer Res, 2005, 65(18): 8193-8199.
  • 2Liu RZ, Graham K, Glubrecht DD, et al. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy[J]. Am J Pathol, 2011, 178(3): 997-1008.
  • 3Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784-2795.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. Arch Pathol Lab Med, 2007, 131(1): 18-43.
  • 5Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011, 22(8): 1736-1747.
  • 6Schug TT, Berry DC, Shaw NS, et al. Opposing effects of retinoic acid on cell growth result from alternate ~ctivation of two different nuclear receptors[J]. Cell, 2007, 129(4); 723- 733.
  • 7Huseein MR, Abd-Elwahed SR, Abdulwahed AR. Alterations of estrogen receptors, progesterone receptors and CerbB2 oncogene protein expression in ductal carcinomas of the breast[J]. Cell Boil Int, 2008, 32(6): 698-707.
  • 8Strauss B. Best hope or last hope : access ~to phase clinical trials of HER2/neu for advanced stage breast cancer patients[J]. J Adv Nurs, 2000, 31 (2): 259-266.
  • 9Engel RH, Kaklamani VG. HER2-positive breast cancer: current and future treatment strategies[J]. Drugs, 2007, 67(9): 1329-1341.
  • 10Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas[J]. Virchows Arch, 2005, 447(4): 688-694.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部